Skip to main content

Select Drug Profiles

Payers' Guide, FDA Approvals

Perjeta: A New Option for Patients with HER2-Positive Metastatic Breast Cancer

Alice Goodman, Medical Writer

FDA Approvals, Payers' Guide

Trends in the 2013 Pharmaceutical Pipeline

Dalia Buffery, MA, ABD, Atheer A. Kaddis, PharmD

Payers' Guide, FDA Approvals

Iclusig: A New Treatment Option for Adults with CML or Ph+ ALL that Is Resistant/ Intolerant to Previous Therapy with TKIs

Lynne Lederman, PhD, Medical Writer

Payers' Guide, FDA Approvals

Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients

Payers' Guide, FDA Approvals

Rayos: A Novel Oral Delayed-Release Prednisone for the Treatment of Rheumatoid Arthritis and Other Inflammatory Diseases

Alice Goodman, Medical Writer

Payers' Guide, FDA Approvals

Xeljanz: A New Treatment Option for Patients with Rheumatoid Arthritis

Alice Goodman, Medical Writer

Payers' Guide, FDA Approvals

Tudorza Pressair: A Novel Oral Inhalation Therapy for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease–Associated Bronchospasm

Payers' Guide, FDA Approvals

Vascepa: First EPA-Only Omega-3 Therapy Approved by the FDA for Severe Hypertriglyceridemia

Payers' Guide, FDA Approvals

Eliquis Approved by the FDA to Reduce the Risks of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

Payers' Guide, FDA Approvals

The Health Burden of Multiple Myeloma: Subcutaneous Velcade a New, Convenient Route of Administration Option

Rhonda Williams, Medical Writer

Page 179 of 244
Results 1781 - 1790 of 2434